Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of UP-818-CC Injection in Healthy Chinese Subjects After Single-dose and Multiple-dose Intravenous Infusion

NCT07355621 is registered in ClinicalTrials.gov with EnliTISA (Shanghai) Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07355621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07355621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of UP-818-CC Injection in Healthy Chinese Subjects After Single-dose and Multiple-dose Intravenous Infusion
Lead sponsor
EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 14, 2022
Completion date
February 20, 2023
Enrollment
73 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects